Abbott announced a definitive agreement to acquire Exact Sciences in a cash deal valued at roughly $21–23 billion, paying $105 per share and folding Exact’s cancer‑screening portfolio into Abbott’s diagnostics business. The acquisition brings market-leading tests—Cologuard, Oncotype DX, Oncodetect and Cancerguard—under Abbott’s global commercial reach and is expected to close in mid‑2026 pending approvals. Exact Sciences reported strong revenue trends from its colorectal and emerging multi‑cancer and MRD assays; Abbott said the purchase will be immediately accretive to revenue growth and gross margin. The companies highlighted plans to scale earlier detection and precision oncology offerings, preserve Exact’s Madison operations, and retain senior Exact executives in advisory roles during integration. Analysts flagged regulatory and payor scrutiny as potential execution risks but noted the deal materially expands Abbott’s diagnostics footprint and positions it to capture a larger share of the fast‑growing cancer screening and precision oncology market estimated in the tens of billions of dollars.